Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Neuroendocrinology ; 54(5): 439-46, 1991 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-1660963

RESUMO

Chronic administration of corticosteroids results in a suppression of the hypothalamo-pituitary-adrenocortical (HPA) axis. The time course of the recovery of the HPA axis depends on the dose and duration of corticosteroid administration. We investigated the recovery of the HPA axis after 14 days of prednisolone administration to rats at a dose of 2.0 mg/rat/day via the drinking water (188 mumol/l). The in vitro corticosterone production by dispersed adrenal cells in response to increasing concentrations of ACTH had recovered 3 days after stopping prednisolone administration. In parallel the initially suppressed plasma corticosterone concentrations had recovered after 3 days, while the pituitary ACTH content had recovered after 5 days. We investigated the possibility to enhance the speed of the recovery of the HPA axis by the simultaneous administration of two drugs with known CRF-stimulating activity via the drinking water. Caffeine in a dose of 100 mg/kg body weight enhanced the recovery of the prednisolone-suppressed HPA axis significantly. One day after the end of prednisolone administration a significant increase in the adrenal weight, in the corticosterone production by dispersed adrenal cells, as well as in the plasma corticosterone concentrations, and in the pituitary ACTH content was observed in the caffeine-treated rats. Chlorimipramine (20 mg/kg body weight), on the other hand, did not influence the prednisolone-mediated suppression of the HPA axis.(ABSTRACT TRUNCATED AT 250 WORDS)


Assuntos
Córtex Suprarrenal/fisiologia , Cafeína/farmacologia , Hipotálamo/fisiologia , Hipófise/fisiologia , Prednisolona/farmacologia , Córtex Suprarrenal/anatomia & histologia , Córtex Suprarrenal/efeitos dos fármacos , Hormônio Adrenocorticotrópico/metabolismo , Hormônio Adrenocorticotrópico/farmacologia , Animais , Peso Corporal/efeitos dos fármacos , Clomipramina/farmacologia , Corticosterona/biossíntese , Corticosterona/metabolismo , Feminino , Hipotálamo/efeitos dos fármacos , Cinética , Tamanho do Órgão/efeitos dos fármacos , Hipófise/efeitos dos fármacos , Ratos
2.
Mol Cell Endocrinol ; 72(2): 95-102, 1990 Aug 20.
Artigo em Inglês | MEDLINE | ID: mdl-1980898

RESUMO

Suramin is a polyanionic compound which has been used in the treatment of trypanosomiasis and acquired immunodeficiency syndrome (AIDS), while preliminary success has been reported in the treatment of cancer. However, suramin also causes adrenal insufficiency. We have previously reported that suramin selectively inhibited corticotropin (ACTH)-stimulated corticosterone release by dispersed adrenal cells in a dose-dependent manner via a direct interaction with the ACTH molecule. The present study was undertaken in order to investigate the effect of suramin on hormone release by dispersed rat anterior pituitary cells. Suramin at a concentration of 100 microM inhibited both basal and secretagogue-stimulated ACTH release by cells cultured in minimal essential medium (MEM) only, while it had no effect on ACTH release by cells cultured in MEM + 10% fetal calf serum (FCS) or MEM + 0.1% bovine serum albumin (BSA). In addition, suramin also caused a parallel decrease of prolactin (PRL) and growth hormone (GH) release by cells cultured in MEM only, suggesting a toxic, rather than a selective effect of suramin on anterior pituitary cells cultured in MEM only. In addition, suramin potentiated the effect of thyrotropin-releasing hormone (TRH) on PRL release by cells cultured in MEM + 10% FCS and suppressed the inhibitory effect of dopamine (DA) on PRL release by cells cultured in MEM + 10% FCS and in MEM + 0.1% BSA. Comparable suppressive effects of suramin on growth hormone-releasing hormone (GHRH)-stimulated and somatostatin (SRIH)-inhibited GH release were found in cells cultured in MEM + 0.1% BSA but not in cells cultured in MEM + 10% FCS.(ABSTRACT TRUNCATED AT 250 WORDS)


Assuntos
Adeno-Hipófise/metabolismo , Hormônios Adeno-Hipofisários/metabolismo , Suramina/farmacologia , Hormônio Adrenocorticotrópico/metabolismo , Animais , Células Cultivadas , Hormônio Liberador da Corticotropina/farmacologia , Meios de Cultura , Sinergismo Farmacológico , Feminino , Hormônio Foliculoestimulante/metabolismo , Hormônio do Crescimento/metabolismo , Hormônio Liberador de Hormônio do Crescimento/farmacologia , Hormônio Luteinizante/metabolismo , Masculino , Adeno-Hipófise/efeitos dos fármacos , Prolactina/metabolismo , Ratos , Somatostatina/farmacologia , Hormônio Liberador de Tireotropina/farmacologia
3.
Endocrinology ; 126(1): 666-8, 1990 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-2152879

RESUMO

Suramin, a polyanionic compound which has been used in the treatment of trypanosomiasis and oncocerciasis, has recently been used in treatment of AIDS, while preliminary success has been reported in the treatment of cancer. However, suramin also causes adrenal insufficiency. The present study was undertaken in order to investigate the effect of suramin on ACTH-stimulated steroid production by dispersed rat adrenal cells. It was shown that suramin at concentrations of 10(-4)-10(-3) M inhibits ACTH-stimulated corticosterone release in a dose-dependent manner IC50 (2.10(-4) M). In addition, suramin caused a parallel decrease in ACTH-stimulated pregnenolone, progesterone and corticosterone release, suggesting that suramin does not affect corticosteroidogenesis via an inhibition of its regulatory enzymes. Suramin at 10(-4) M did not inhibit cholera toxin (10 mg/l)-, forskolin (5 microM)- and dbcAMP (5 mM)-stimulated corticosterone release, while cholera toxin completely overcame the inhibitory effects of very high concentrations of suramin (up till 10(-3) M), on ACTH-stimulated corticosterone release. Finally, chromatographic studies with a matrex gel showed that suramin directly interacted with the ACTH molecule. In conclusion, suramin at "therapeutic" concentrations (10(-4) M and higher) prevents ACTH-stimulated corticosterone release probably via a direct interaction with the ACTH molecule.


Assuntos
Córtex Suprarrenal/metabolismo , Hormônio Adrenocorticotrópico/farmacologia , Corticosterona/metabolismo , Suramina/farmacologia , Córtex Suprarrenal/citologia , Animais , Fenômenos Biomecânicos , Toxina da Cólera/farmacologia , Cromatografia em Gel , Corticosterona/antagonistas & inibidores , Técnicas Citológicas , Concentração Osmolar
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...